Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expected to Announce Quarterly Sales of $33.11 Million
Equities analysts predict that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will report $33.11 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Halozyme Therapeutics’ earnings. The highest sales estimate is $34.21 million and the lowest is $32.31 million. Halozyme Therapeutics reported sales of $33.34 million during the same quarter last year, which would suggest a negative year over year growth rate of 0.7%. The business is scheduled to report its next quarterly earnings report after the market closes on Tuesday, August 8th.
On average, analysts expect that Halozyme Therapeutics will report full year sales of $33.11 million for the current fiscal year, with estimates ranging from $124.00 million to $135.68 million. For the next fiscal year, analysts anticipate that the firm will post sales of $164.17 million per share, with estimates ranging from $135.27 million to $186.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.01. The company had revenue of $29.60 million during the quarter, compared to the consensus estimate of $30.79 million. During the same quarter last year, the firm posted ($0.16) EPS. The company’s revenue was down 30.4% compared to the same quarter last year.
HALO has been the subject of a number of recent research reports. Barclays PLC restated an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, July 1st. BMO Capital Markets assumed coverage on shares of Halozyme Therapeutics in a report on Monday, April 17th. They issued a “market perform” rating and a $14.00 target price on the stock. Zacks Investment Research raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 12th. Finally, ValuEngine raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $14.84.
Large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in Halozyme Therapeutics during the first quarter worth about $122,000. Teacher Retirement System of Texas acquired a new position in Halozyme Therapeutics during the second quarter worth about $129,000. Stifel Financial Corp acquired a new position in Halozyme Therapeutics during the first quarter worth about $187,000. Karp Capital Management Corp acquired a new position in Halozyme Therapeutics during the first quarter worth about $188,000. Finally, IFP Advisors Inc increased its position in Halozyme Therapeutics by 1.6% in the second quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 226 shares during the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Halozyme Therapeutics (NASDAQ:HALO) opened at 13.06 on Monday. Halozyme Therapeutics has a 1-year low of $8.18 and a 1-year high of $15.20. The firm has a 50-day moving average of $13.39 and a 200-day moving average of $13.07. The stock’s market capitalization is $1.68 billion.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.